Biohaven is powering ahead with its bold ambition to sharply reduce R&D spending—even as analysts warn the company will need to be even stricter with its expenditures. | Biohaven is powering ahead ...

BioAtla is laying off 70% of its workforce as the antibody biotech mulls whether to sell off its remaining assets. | BioAtla is laying off 70% of its workforce as the antibody biotech mulls whether to ...

Regencell Bioscience (RGC 4.01%) is an early-stage bioscience company. That alone should be enough to keep most investors on ...

"If the neurons fire in a specific pattern, the Doom guy shoots." The post Researchers Get Human Brain Cells Running Doom ...

A Senate hearing probed whether the Food and Drug Administration's process for approving rare-disease therapies is ...

RASolute 302 Phase 3 catalyst, cash runway, and valuation risks for daraxonrasib. Read more macro analysis here.

The structures that UpNano produces in the 3D printer are so small that they are recognizable neither with the naked eye nor with a strong optical microscope. Only under a scanning electron microscope ...

Comfort with ambiguity isn’t about tolerance for chaos. Rather it's an opportunity to be creative, craft a vision, and build ...

Rare Disease Day is held on the last day of February to raise awareness for rare diseases and address drug development ...

A clinical pharmacist and the in-country technical consultant for the Commonwealth Partnership for Antimicrobial Stewardship under the Commonwealth Pharmacists Association, Moshood Lawal, has called ...

In many industries, contact centers are still thought of as cost centers—places to handle complaints and basic inquiries at ...

Modern batch processing relies on flexible ISA-88–based software that streamlines recipe creation, coordinates tasks across multiple units and enables efficient execution of multistage production ...